Novartis CEO Vas Narasimhan sees his company on a good growth trajectory in the coming years. In an interview with Swiss paper Finanz und Wirtschaft (Finance and Economy), he also emphasised his commitment to Switzerland as a business location. + Get the most important news from Switzerland in your inbox Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028. This will be made possible by eight to nine medicines, which Novartis expects to generate billions in sales. “The bigger challenge is to replenish the mid- and late-stage development pipeline so that we can grow until 2030 and beyond,” he told Finanz and Wirtschaft. According to Narasimhan, the expiry of patents over the next few years is also not a threat to Novartis’s growth target. “Key products such as the psoriasis treatment Cosentyx, whose patent protection extends until the end of the decade, and numerous other products that are already on the market, as well ...
